[go: up one dir, main page]

SG11201906969PA - Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides - Google Patents

Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides

Info

Publication number
SG11201906969PA
SG11201906969PA SG11201906969PA SG11201906969PA SG11201906969PA SG 11201906969P A SG11201906969P A SG 11201906969PA SG 11201906969P A SG11201906969P A SG 11201906969PA SG 11201906969P A SG11201906969P A SG 11201906969PA SG 11201906969P A SG11201906969P A SG 11201906969PA
Authority
SG
Singapore
Prior art keywords
international
cambridge
activating oncogene
pct
street
Prior art date
Application number
SG11201906969PA
Inventor
Eric Yi-Chun Huang
Sze-Wah Tse
Jared Iacovelli
Kristine Mckinney
Nicholas Valiante
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of SG11201906969PA publication Critical patent/SG11201906969PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 09 August 2018 (09.08.2018) WIPO I PCT (51) International Patent Classification: A61K 39/00 (2006.01) A61K 39/39 (2006.01) (21) International Application Number: PCT/US2018/016510 (22) International Filing Date: Published: — with international search report (Art. 21(3)) (25) Filing Language: (26) Publication Language: (30) Priority Data: 01 February 2018 (01.02.2018) English English 62/453,465 01 February 2017 (01.02.2017) US 62/467,063 03 March 2017 (03.03.2017) US 62/490,523 26 April 2017 (26.04.2017) US 62/541,571 04 August 2017 (04.08.2017) US (71) Applicant: MODERNATX, INC. [US/US]; 200 Technol- ogy Square, Cambridge, MA 02139 (US). (72) Inventors: HUANG, Eric Yi-chun; 90 Wareham Street, Unit 302, Boston, MA 02118 (US). TSE, Sze-Wah; 200 Technology Square, Cambridge, MA 02139 (US). IACOV- ELLI, Jared; 20 Rich Street #2, Waltham, MA 02451 (US). MCKINNEY, Kristine; 73 Highland Ave, Cambridge, MA 02139 (US). VALIANTE, Nicholas; 70 Norfolk Street, Cambridge, MA 02139 (US). (74) Agent: MANDRAGOURAS, Amy, E. et al.; Nelson Mullins Riley & Scarborough LLP, One Post Office Square, Boston, MA 02109-2127 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, N KM, ML, MR, NE, SN, TD, TG). N 71' 71' (54) Title: IMMUNOMODULATORY THERAPEUTIC MRNA COMPOSITIONS ENCODING ACTIVATING ONCOGENE MU- 00 TATION PEPTIDES O N mutation peptide and an mRNA encoding a polypeptide that enhances immune responses to the activating oncogene mutation peptide, (57) : The disclosure features immunomodulatory therapeutic compositions of an mRNA encoding an activating oncogene O for example an mRNA encoding an immune potentiator. The disclosure also features methods of using the same, for example, to stimulate anti-cancer immune responses. oncio °nolo Ho Ho Ho mo Immo oimIE (10) International Publication Number WO 2018/144775 Al
SG11201906969PA 2017-02-01 2018-02-01 Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides SG11201906969PA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762453465P 2017-02-01 2017-02-01
US201762467063P 2017-03-03 2017-03-03
US201762490523P 2017-04-26 2017-04-26
US201762541571P 2017-08-04 2017-08-04
PCT/US2018/016510 WO2018144775A1 (en) 2017-02-01 2018-02-01 Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides

Publications (1)

Publication Number Publication Date
SG11201906969PA true SG11201906969PA (en) 2019-08-27

Family

ID=61244714

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906969PA SG11201906969PA (en) 2017-02-01 2018-02-01 Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides

Country Status (15)

Country Link
US (3) US20190351039A1 (en)
EP (1) EP3576780A1 (en)
JP (2) JP2020514321A (en)
KR (1) KR20190110612A (en)
CN (2) CN117224710A (en)
AU (1) AU2018214556A1 (en)
BR (1) BR112019015797A2 (en)
CA (1) CA3051252A1 (en)
CL (1) CL2019002134A1 (en)
CO (1) CO2019009234A2 (en)
EA (1) EA201991804A1 (en)
IL (1) IL268361A (en)
MX (2) MX2019009070A (en)
SG (1) SG11201906969PA (en)
WO (1) WO2018144775A1 (en)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3981437T3 (en) 2014-04-23 2025-02-24 Modernatx, Inc. Nucleic acid vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
HK1256498A1 (en) 2015-07-30 2019-09-27 Modernatx, Inc. Concatemeric peptide epitope rnas
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
ES2969082T3 (en) 2015-09-17 2024-05-16 Modernatx Inc Compounds and compositions for intracellular administration of therapeutic agents
MA46080A (en) 2015-10-22 2019-07-10 Modernatx Inc NUCLEIC ACID VACCINES AGAINST VARICELLA ZONA VIRUS (VZV)
EP4349404A3 (en) 2015-10-22 2024-06-19 ModernaTX, Inc. Respiratory virus vaccines
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
MA46316A (en) 2015-10-22 2021-03-24 Modernatx Inc HUMAN CYTOMEGALOVIRUS VACCINE
LT3386484T (en) 2015-12-10 2022-06-10 Modernatx, Inc. Compositions and methods for delivery of therapeutic agents
US10799463B2 (en) 2015-12-22 2020-10-13 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
WO2017201342A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
AU2017326423B2 (en) 2016-09-14 2023-11-09 Modernatx, Inc. High purity RNA compositions and methods for preparation thereof
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. VACCINE AGAINST THE HUMANE CYTOMEGALOVIRUS
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
EP3555289A1 (en) 2016-12-13 2019-10-23 ModernaTX, Inc. Rna affinity purification
SG11201906969PA (en) 2017-02-01 2019-08-27 Modernatx Inc Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS VACCINE
MX2019011004A (en) 2017-03-15 2020-08-10 Modernatx Inc Compounds and compositions for intracellular delivery of therapeutic agents.
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
US11752206B2 (en) * 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
EP3595676A4 (en) 2017-03-17 2021-05-05 Modernatx, Inc. RNA-BASED VACCINES AGAINST ZOONOTIC DISEASES
US11905525B2 (en) 2017-04-05 2024-02-20 Modernatx, Inc. Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
US12077501B2 (en) 2017-06-14 2024-09-03 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
MA49421A (en) 2017-06-15 2020-04-22 Modernatx Inc RNA FORMULATIONS
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. Analytical hplc methods
EP3668971B8 (en) 2017-08-18 2024-05-29 ModernaTX, Inc. Rna polymerase variants
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. Methods for hplc analysis
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. Methods of making lipid nanoparticles
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. Zika virus rna vaccines
EP3746090A4 (en) 2018-01-29 2021-11-17 ModernaTX, Inc. RSV RNA VACCINES
AU2019216307A1 (en) * 2018-01-30 2020-07-09 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells
IL319091A (en) 2018-06-06 2025-04-01 Massachusetts Inst Technology Circular rna for translation in eukaryotic cells
EP3827262A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
EP3827261A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
JP2022500443A (en) * 2018-09-13 2022-01-04 モデルナティーエックス， インコーポレイテッド Modified mRNA for treating progressive familial intrahepatic cholestasis disorder
SG11202101619UA (en) * 2018-09-18 2021-04-29 Univ Gent Therapeutic nanoparticles and methods of use thereof
EP3853202A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
JP7640452B2 (en) 2018-09-19 2025-03-05 モデルナティエックス インコーポレイテッド Highly pure PEGylated lipids and their uses
CA3113025A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
CA3113651A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
TW202039534A (en) * 2018-12-14 2020-11-01 美商美國禮來大藥廠 Kras variant mrna molecules
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
CN113795579A (en) 2019-02-20 2021-12-14 摩登纳特斯有限公司 RNA polymerase variants for co-transcriptional capping
WO2020176809A1 (en) * 2019-02-27 2020-09-03 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
EP3938507A4 (en) 2019-03-11 2023-02-22 ModernaTX, Inc. Fed-batch in vitro transcription process
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
EP3972653A1 (en) 2019-05-22 2022-03-30 Massachusetts Institute of Technology Circular rna compositions and methods
JP7638972B2 (en) 2019-09-19 2025-03-04 モデルナティエックス インコーポレイテッド Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents - Patents.com
WO2021072172A1 (en) * 2019-10-09 2021-04-15 Translate Bio, Inc. Compositions, methods and uses of messenger rna
US20240158458A1 (en) * 2019-10-15 2024-05-16 Moderna TX, Inc. Mrnas encoding immune modulating polypeptides and uses thereof
CA3161450A1 (en) * 2019-11-12 2021-05-20 Actym Therapeutics, Inc. Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
TW202131945A (en) * 2019-11-15 2021-09-01 日商第一三共股份有限公司 Nucleic acid lipid nanoparticle vaccine encapsulating hpv mrna
WO2021113777A2 (en) 2019-12-04 2021-06-10 Orna Therapeutics, Inc. Circular rna compositions and methods
KR102410556B1 (en) * 2020-01-16 2022-06-20 아주대학교산학협력단 Peptide for targeting to mitochondria
WO2021155267A2 (en) * 2020-01-30 2021-08-05 Modernatx, Inc. Mrnas encoding metabolic reprogramming polypeptides and uses thereof
CN111440825A (en) * 2020-04-07 2020-07-24 嘉晨西海(杭州)生物技术有限公司 Method for loading mRNA (messenger ribonucleic acid) by liposome
JP7457833B2 (en) 2020-04-09 2024-03-28 ヴァーヴ・セラピューティクス，インコーポレーテッド Base editing of ANGPTL3 and methods of using it to treat disease
TW202204622A (en) * 2020-04-09 2022-02-01 大陸商蘇州艾博生物科技有限公司 Nucleic acid vaccines for coronavirus
IL297419B2 (en) 2020-04-22 2025-02-01 BioNTech SE Coronavirus vaccine
IL297502A (en) * 2020-04-24 2022-12-01 Genexine Inc Method for treating cervical cancer
WO2021229502A1 (en) 2020-05-15 2021-11-18 Crispr Therapeutics Ag Messenger rna encoding cas9 for use in genome-editing systems
KR20230083266A (en) * 2020-07-31 2023-06-09 콤바인드 테라퓨틱스, 인코포레이션 Compositions and methods for improved vaccination
WO2022031021A1 (en) * 2020-08-04 2022-02-10 성균관대학교산학협력단 Mrna vaccine comprising adjuvant capable of kinetic control
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
CN116917470A (en) * 2020-10-14 2023-10-20 达冕生物有限公司 PAN-RAS mRNA cancer vaccine
IL302215A (en) 2020-10-20 2023-06-01 St Pharm Co Ltd Oligonucleotide for 5'-capped rna synthesis
CN116710115A (en) 2020-11-20 2023-09-05 思维疗法股份有限公司 Compositions and methods for optimized peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) * 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
CA3202227A1 (en) * 2020-11-20 2022-05-27 Think Therapeutics, Inc. Compositions and methods for optimized peptide vaccines
EP4262819A4 (en) * 2020-12-21 2024-12-04 Beam Therapeutics Inc. Nanomaterials comprising ester-linked acetals
US12329811B2 (en) 2021-01-11 2025-06-17 Modernatx, Inc. Seasonal RNA influenza virus vaccines
EP4293043A4 (en) * 2021-02-10 2025-09-10 Shanghai Genbase Biotechnology Co Ltd Epitope peptidide of a RAS-G13D mutant and T cell receptor for recognition of a RAS-G13D mutant
IL305644A (en) * 2021-03-05 2023-11-01 Modernatx Inc VLP enteroviral vaccines
AU2022245391A1 (en) * 2021-03-26 2023-10-12 The Translational Genomics Research Institute Methods and compounds for neoantigen vaccines
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
WO2022240960A1 (en) 2021-05-14 2022-11-17 Crispr Therapeutics Ag Mrna large scale synthesis and purification
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
CN113264842B (en) * 2021-07-21 2022-03-01 苏州科锐迈德生物医药科技有限公司 Lipid compound, lipid carrier containing same, nucleic acid lipid nanoparticle composition and pharmaceutical preparation
CN115703713B (en) * 2021-08-13 2025-06-10 广州谷森制药有限公司 Cationic lipid compounds
WO2023044343A1 (en) * 2021-09-14 2023-03-23 Renagade Therapeutics Management Inc. Acyclic lipids and methods of use thereof
WO2023061460A1 (en) * 2021-10-15 2023-04-20 厦门赛诺邦格生物科技股份有限公司 Nitrogen-containing cationic lipid and application thereof
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
EP4452298A4 (en) * 2021-12-22 2025-11-19 Memorial Sloan Kettering Cancer Center Cells for the expression of FAS ligands and CFLIP polypeptides and uses thereof
WO2023125974A1 (en) * 2021-12-31 2023-07-06 广州国家实验室 Mrna vaccine
US20250101078A1 (en) * 2022-01-21 2025-03-27 T-Knife Gmbh Antigen recognizing construct that binds specific peptide with determinable affinity and t cell receptor having antigenic specificity for kras as well as corresponding nucleic acid sequence, vector, host cell, pharmaceutical composition and kit
JP2025509648A (en) * 2022-03-16 2025-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング TUMOR ANTIGENS, COMPOUNDS COMPRISING TUMOR ANTIGENS KRAS, TPX2 OR AURKA AND USES THEREOF - Patent application
CN116655486A (en) * 2022-05-19 2023-08-29 仁景(苏州)生物科技有限公司 Long-chain alkyl ester amine compound and its preparation method and application in nucleic acid delivery
CN115286674A (en) * 2022-06-13 2022-11-04 湖北英纳氏生物科技有限公司 A kind of cationic liposome and preparation method thereof
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
CN115869332A (en) * 2022-10-27 2023-03-31 北京新合睿恩生物医疗科技有限公司 mRNA drug with low expression in liver after delivery into body and preparation method thereof
WO2024102332A1 (en) * 2022-11-07 2024-05-16 Himv Llc Vaccine compositions comprising a neoantigen of kras
WO2024107827A1 (en) * 2022-11-16 2024-05-23 The Broad Institute, Inc. Therapeutic exploitation of sting channel activity
WO2024112821A1 (en) * 2022-11-22 2024-05-30 Elixirgen Therapeutics, Inc. Antigens for cancer immunotherapy
US20250333728A1 (en) 2022-11-24 2025-10-30 Suzhou Abogen Biosciences Co., Ltd. Utr molecule for increasing protein expression level
WO2024136608A1 (en) * 2022-12-23 2024-06-27 한미약품 주식회사 Antigenic peptide having multiple kras variant peptides linked thereto, nucleic acid encoding the same, and use thereof
WO2024147556A1 (en) * 2023-01-05 2024-07-11 의료법인 명지의료재단 Composition for anticancer vaccine comprising k-ras mutant multiple epitope polypeptide as active ingredient
WO2024151877A2 (en) 2023-01-11 2024-07-18 Engage Biologics Inc. Non-viral expression systems and methods of use thereof
WO2024199359A1 (en) * 2023-03-28 2024-10-03 江苏瑞科生物技术股份有限公司 Liposome adjuvant system containing cyclic dinucleotide molecule, and preparation method therefor
WO2024211447A1 (en) * 2023-04-03 2024-10-10 Chrysalis Biotherapeutics Tp508 mrnas
CN117604031B (en) * 2023-04-20 2025-05-09 龙岩学院 An in vitro transcription system for feline coronavirus S protein mRNA and its construction method
TW202530174A (en) * 2023-10-19 2025-08-01 大陸商仁景（蘇州）生物科技有限公司 Lipid compounds and lipid nanoparticles for delivery
US20250144234A1 (en) 2023-11-02 2025-05-08 Capstan Therapeutics Inc. RNA for In vivo Transfection with Increased Expression
KR20250148433A (en) * 2024-03-29 2025-10-14 한미약품 주식회사 Antigen peptide with multiple KRAS variants peptide linked together, nucleic acid encoding same, and use thereof
CN120209109A (en) * 2024-03-29 2025-06-27 仁景(苏州)生物科技有限公司 STING protein mutants, nucleic acids encoding the same and their applications

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8613481D0 (en) 1986-06-04 1986-07-09 Diatech Ltd Translation of mrna
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6867195B1 (en) 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
CA2174863A1 (en) 1993-11-26 1995-06-01 Yuti Luis Alberto Chernajovsky Translational enhancer dna
US6027726A (en) 1994-09-30 2000-02-22 Inex Phamaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
US5824497A (en) 1995-02-10 1998-10-20 Mcmaster University High efficiency translation of mRNA molecules
US6503503B1 (en) 1997-05-13 2003-01-07 Duke University Allogeneic cellular vaccine
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB2328689A (en) 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
US20060009633A9 (en) 1997-11-13 2006-01-12 Genset, S.A. Complementary DNAs encoding proteins with signal peptides
NO309798B1 (en) 1999-04-30 2001-04-02 Targovax As Peptide composition, as well as pharmaceutical composition and cancer vaccine including the peptide composition
ES2340499T3 (en) 2001-06-05 2010-06-04 Curevac Gmbh TUMOR ANTIGEN ARNM STABILIZED WITH AN INCREASED G / C CONTENT.
JP4371812B2 (en) 2001-09-28 2009-11-25 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ MicroRNA molecules
WO2003048202A2 (en) 2001-12-03 2003-06-12 Asahi Kasei Pharma Corporation Nf-kappab activating genes
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
GB0221574D0 (en) 2002-09-17 2002-10-23 Isis Innovation Treatments
US20040223949A1 (en) 2002-10-22 2004-11-11 Sunnybrook And Women's College Health Sciences Center Aventis Pasteur, Ltd. Vaccines using high-dose cytokines
JP2006517785A (en) 2002-10-29 2006-08-03 ジェネンテック・インコーポレーテッド Novel compositions and methods for the treatment of immune related diseases
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
CA2898163C (en) 2002-12-16 2016-10-11 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
EP4174179B1 (en) 2005-08-23 2025-05-07 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
EP2479285B1 (en) 2006-01-05 2014-05-14 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
CA2635616A1 (en) 2006-01-05 2007-07-19 Carlo M. Croce Microrna expression abnormalities in pancreatic endocrine and acinar tumors
ES2448491T3 (en) 2006-03-02 2014-03-14 The Ohio State University Research Foundation MicroRNA expression profile associated with pancreatic cancer
EP2004666B1 (en) 2006-03-27 2014-09-03 Globeimmune, Inc. Ras mutation and compositions and methods related thereto
EP2115138A2 (en) 2006-09-19 2009-11-11 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
JP5501766B2 (en) 2006-11-01 2014-05-28 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション MicroRNA expression signature to predict survival and metastasis in hepatocellular carcinoma
CN101622349A (en) 2006-12-08 2010-01-06 奥斯瑞根公司 miR-20 regulated genes and pathways as targets for therapeutic intervention
US8415096B2 (en) 2007-05-23 2013-04-09 University Of South Florida Micro-RNAs modulating immunity and inflammation
WO2008154098A2 (en) 2007-06-07 2008-12-18 Wisconsin Alumni Research Foundation Reagents and methods for mirna expression analysis and identification of cancer biomarkers
CA2693707A1 (en) 2007-07-13 2009-03-05 The Johns Hopkins University B7-dc variants
BRPI0813621A2 (en) 2007-07-27 2017-05-09 Immatics Biotechnologies Gmbh immunotherapy against neuronal and brain tumors
WO2009034172A1 (en) 2007-09-14 2009-03-19 Vrije Universiteit Brussel Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
WO2009046738A1 (en) * 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
US20100323357A1 (en) 2007-11-30 2010-12-23 The Ohio State University Research Foundation MicroRNA Expression Profiling and Targeting in Peripheral Blood in Lung Cancer
US20110165223A1 (en) 2008-01-02 2011-07-07 The Johns Hopkins University Antitumor Immunization by Liposomal Delivery of Vaccine to the Spleen
EP2260110B1 (en) 2008-02-08 2014-11-12 Asuragen, INC. miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
JP2011517932A (en) 2008-02-28 2011-06-23 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション MicroRNA signatures associated with human chronic lymphocytic leukemia (CCL) and uses thereof
EP2112235A1 (en) 2008-04-24 2009-10-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma
WO2009149539A1 (en) 2008-06-10 2009-12-17 Université de Montréal Enhancing antigen-specific cd8+ t cell response using irf-7 mrna
EP2324044A4 (en) 2008-08-04 2012-04-25 Univ Miami STING (INTERFERON GENE STIMULATOR), A REGULATOR OF INDIAN IMMUNE RESPONSES
WO2010018563A2 (en) 2008-08-12 2010-02-18 Rosetta Genomics Ltd. Compositions and methods for the prognosis of lymphoma
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
CN102439169B (en) 2008-11-13 2014-11-19 复旦大学 Compositions and methods for micro-rna expession profiling of colorectal cancer
EP2358902A1 (en) 2008-12-10 2011-08-24 Universität Regensburg Compositions and methods for micro-rna expression profiling of cancer stem cells
EP2246433A1 (en) * 2009-04-30 2010-11-03 Mologen AG Concatamers for immune modulation
WO2010129860A2 (en) 2009-05-08 2010-11-11 The Ohio State University Research Foundation Microrna expression profiling and targeting in chronic obstructive pulmonary disease (copd) lung tissue and methods of use thereof
CA2764609C (en) 2009-06-10 2018-10-02 Alnylam Pharmaceuticals, Inc. Improved cationic lipid of formula i
WO2011076142A1 (en) 2009-12-24 2011-06-30 Fudan University Compositions and methods for microrna expession profiling in plasma of colorectal cancer
WO2011076143A1 (en) 2009-12-24 2011-06-30 Fudan University Compositions and methods for microrna expression profiling of lung cancer
EP2341145A1 (en) 2009-12-30 2011-07-06 febit holding GmbH miRNA fingerprint in the diagnosis of diseases
WO2011094683A2 (en) 2010-01-29 2011-08-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of identifying myelodysplastic syndromes
EP2354246A1 (en) 2010-02-05 2011-08-10 febit holding GmbH miRNA in the diagnosis of ovarian cancer
WO2011113030A2 (en) 2010-03-11 2011-09-15 H.Lee Moffitt Cancer Center & Research Institute Human cancer micro-rna expression profiles predictive of chemo-response
CN105648056A (en) 2010-05-14 2016-06-08 综合医院公司 Composite and method for detecting tumor specific novel antigen
WO2011157294A1 (en) 2010-06-16 2011-12-22 Universita' Degli Studi Di Padova Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto
PL4066819T3 (en) * 2010-08-31 2023-06-05 Glaxosmithkline Biologicals Sa Small liposomes for delivery of immunogen-encoding rna
EP4066857B1 (en) * 2010-08-31 2022-12-21 GlaxoSmithKline Biologicals SA Pegylated liposomes for delivery of immunogen-encoding rna
CN104531812A (en) 2010-10-01 2015-04-22 现代治疗公司 Engineered nucleic acids and methods of use thereof
LT2633034T (en) 2010-10-26 2018-03-26 Friedrich-Alexander-Universität Erlangen-Nürnberg NFkB SIGNAL PATH-MANIPULATED DENDRITIC CELLS
EP3202760B1 (en) 2011-01-11 2019-08-21 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
WO2012151212A1 (en) 2011-05-01 2012-11-08 University Of Rochester Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof
CA2835179A1 (en) 2011-05-06 2012-11-15 Xentech Markers for cancer prognosis and therapy and methods of use
EP3569607A1 (en) 2011-05-11 2019-11-20 Exosome Diagnostics, Inc. Nucleic acid extraction from heterogeneous biological materials
WO2012158736A1 (en) * 2011-05-17 2012-11-22 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof for non-human vertebrates
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
RU2670745C9 (en) 2011-05-24 2018-12-13 Бионтех Рна Фармасьютикалс Гмбх Individualised vaccines for cancer
ES2663360T3 (en) 2011-06-08 2018-04-12 Translate Bio, Inc. Cleavable lipids
JP5965481B2 (en) 2011-07-15 2016-08-03 レオ ファーマ アクティーゼルスカブ MicroRNA profiling for diagnosis of cutaneous T-cell lymphoma (CTCL)
WO2013033640A1 (en) 2011-09-01 2013-03-07 Allegro Diagnostics Corp. Methods and compositions for detecting cancer based on mirna expression profiles
SG10201903119QA (en) 2011-09-06 2019-05-30 Agency Science Tech & Res Polypeptide vaccine
US20140243240A1 (en) 2011-10-26 2014-08-28 Georgetown University microRNA EXPRESSION PROFILING OF THYROID CANCER
WO2013078199A2 (en) 2011-11-23 2013-05-30 Children's Medical Center Corporation Methods for enhanced in vivo delivery of synthetic, modified rnas
ES2921724T1 (en) 2011-12-07 2022-08-31 Alnylam Pharmaceuticals Inc Biodegradable lipids for the administration of active agents
PL2791160T3 (en) * 2011-12-16 2022-06-20 Modernatx, Inc. Modified mrna compositions
WO2013103659A1 (en) 2012-01-04 2013-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus
WO2013116126A1 (en) 2012-02-01 2013-08-08 Merck Sharp & Dohme Corp. Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
CN103547683A (en) * 2012-03-22 2014-01-29 耶鲁大学 KRAS mutations and tumor biology
HK1206779A1 (en) 2012-04-02 2016-01-15 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243949A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
JP2015516989A (en) 2012-04-30 2015-06-18 バーバー, グレン, エヌ.BARBER, Glen, N. Modulation of immune response
CN104685055A (en) * 2012-05-09 2015-06-03 格兰达利斯有限公司 Bifunctional short hairpin RNAs (bi-shRNAs) specific for single nucleotide KRAS mutations
CN104507538B (en) 2012-06-08 2018-04-06 艾杜罗生物科技公司 Compositions and methods for cancer immunotherapy
HK1207666A1 (en) * 2012-07-16 2016-02-05 Kyowa Hakko Kirin Co., Ltd. Rnai pharmaceutical composition capable of suppressing expression of kras gene
US10973892B2 (en) 2012-09-04 2021-04-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
US10093701B2 (en) 2012-09-07 2018-10-09 University Of Miami Fusion proteins for promoting an immune response, nucleic acids encoding same, and methods of making and use thereof
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
EP2925348B1 (en) 2012-11-28 2019-03-06 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
AU2013374345A1 (en) 2013-01-17 2015-08-06 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
CA2898474A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
HK1220122A1 (en) 2013-03-09 2017-04-28 Modernatx, Inc. Heterologous untranslated regions for mrna
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
AU2014233424B2 (en) 2013-03-15 2017-03-16 The Trustees Of The University Of Pennsylvania Vaccines with biomolecular adjuvants
WO2014166501A2 (en) 2013-04-10 2014-10-16 Skau Aps Use of immune suppressive peptides as adjuvants
JP2016524593A (en) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター Compositions and methods for altering second messenger signaling
JP2016518140A (en) 2013-05-03 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Cyclic dinucleotide derivatization of type I interferon
EP2996472B1 (en) 2013-05-18 2019-03-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
US9724408B2 (en) 2013-05-18 2017-08-08 Aduro Biotech, Inc. Compositions and methods for activating stimulator of interferon gene-dependent signalling
WO2015017652A1 (en) 2013-07-31 2015-02-05 Memorial Sloan-Kettering Cancer Center Sting crystals and modulators
KR20160065858A (en) 2013-10-21 2016-06-09 드렉셀유니버시티 Use of sting agonists to treat chronic hepatitis b virus infection
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
WO2015077354A1 (en) 2013-11-19 2015-05-28 The University Of Chicago Use of sting agonist as cancer treatment
ES2682038T3 (en) 2013-12-09 2018-09-18 Targovax Asa A mixture of peptides
US10421971B2 (en) 2014-01-15 2019-09-24 The University Of Chicago Anti-tumor therapy
WO2015123532A1 (en) * 2014-02-16 2015-08-20 Globeimmune, Inc. Ras g12r immunotherapy for ras mutation-positive cancers
US10821175B2 (en) 2014-02-25 2020-11-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
AU2015231461B2 (en) 2014-03-17 2021-09-09 Tapimmune Inc. Nucleic acid molecule vaccine compositions and uses thereof
PL3981437T3 (en) * 2014-04-23 2025-02-24 Modernatx, Inc. Nucleic acid vaccines
EP3134546A4 (en) * 2014-04-24 2017-12-06 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
KR20170002563A (en) * 2014-05-06 2017-01-06 타르고바스 에이에스에이 Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
EP3160938B1 (en) 2014-06-25 2020-09-16 Acuitas Therapeutics Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2016046357A1 (en) 2014-09-26 2016-03-31 Bavarian Nordic A/S Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin
MA40737A (en) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center DETERMINANTS OF CANCER RESPONSE TO PD-1 BLOCKED IMMUNOTHERAPY
EP3273944B1 (en) 2015-03-25 2024-11-20 The Regents of The University of Michigan Compositions and methods for delivery of biomacromolecule agents
US10293058B2 (en) 2015-04-22 2019-05-21 Curevac Ag RNA containing composition for treatment of tumor diseases
WO2016176330A1 (en) 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
PE20180670A1 (en) 2015-05-20 2018-04-19 Broad Inst Inc SHARED NEOANTIGENS
CA2989157A1 (en) 2015-06-11 2016-12-15 University Of Miami Cancer treatment and diagnosis
EP3310808A1 (en) * 2015-06-16 2018-04-25 Targovax Asa Mutated fragments of the ras protein
US20180296663A1 (en) 2015-06-17 2018-10-18 Curevac Ag Vaccine composition
ES2937963T3 (en) * 2015-07-21 2023-04-03 Modernatx Inc Infectious disease vaccines
HK1256498A1 (en) * 2015-07-30 2019-09-27 Modernatx, Inc. Concatemeric peptide epitope rnas
CA2993429A1 (en) 2015-07-31 2017-02-09 Tarveda Therapeutics, Inc. Compositions and methods for immuno-oncology therapies
ES2969082T3 (en) * 2015-09-17 2024-05-16 Modernatx Inc Compounds and compositions for intracellular administration of therapeutic agents
EP3359675B1 (en) 2015-10-07 2024-01-03 Nant Holdings IP, LLC Activation of immune-related signalling pathways in cells via optofection
WO2017066256A2 (en) 2015-10-12 2017-04-20 Nantomics, Llc Compositions and methods for viral cancer neoepitopes
WO2017068482A1 (en) 2015-10-19 2017-04-27 Cadila Healthcare Limited New adjuvant and vaccine composition containing the same
WO2017070618A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Cancer vaccines
FI3368507T3 (en) 2015-10-28 2023-03-21 Acuitas Therapeutics Inc New lipids and lipid nanoparticle preparations for delivery of nucleic acids
EP3393511A1 (en) 2015-12-21 2018-10-31 La Jolla Institute for Allergy and Immunology Leveraging immune memory from common childhood vaccines to fight disease
WO2017118702A1 (en) 2016-01-08 2017-07-13 Vaccibody As Neoepitope rna cancer vaccine
JP2019510488A (en) 2016-03-04 2019-04-18 ニューヨーク・ユニバーシティ Viral vector expressing multiple epitopes of tumor associated antigen for inducing anti-tumor immunity
WO2017177204A1 (en) 2016-04-09 2017-10-12 La Jolla Institute For Allergy And Immunology Leveraging immune memory from common childhood vaccines to fight disease
WO2017190242A1 (en) 2016-05-04 2017-11-09 Immunovaccine Technologies Inc. Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
SG11201810332TA (en) 2016-05-27 2018-12-28 Etubics Corp Neoepitope vaccine compositions and methods of use thereof
US12257352B2 (en) 2016-06-20 2025-03-25 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
EP3967324A1 (en) 2016-07-20 2022-03-16 BioNTech SE Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
CN110418636A (en) 2016-08-23 2019-11-05 杰罗米.J.申塔格 Loading of peptides, proteins and nucleic acids into chylomicrons and cholesteryl vesicles in somatic cells
CA3042015A1 (en) * 2016-10-26 2018-05-03 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
WO2018083220A2 (en) 2016-11-04 2018-05-11 Hookipa Biotech Ag Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
SG11201901979SA (en) 2016-11-30 2019-04-29 Advaxis Inc Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
WO2018102585A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations
CN110381997A (en) 2016-12-12 2019-10-25 茂体外尔公司 For treating and preventing the method and composition comprising gene-virus therapy and immunologic test point inhibitor of cancer and infectious diseases
SG11201906969PA (en) 2017-02-01 2019-08-27 Modernatx Inc Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides

Also Published As

Publication number Publication date
KR20190110612A (en) 2019-09-30
JP2023103250A (en) 2023-07-26
JP2020514321A (en) 2020-05-21
EA201991804A1 (en) 2020-02-07
MX2019009070A (en) 2019-10-30
IL268361A (en) 2019-09-26
US10881730B2 (en) 2021-01-05
US20190175727A1 (en) 2019-06-13
US20190351039A1 (en) 2019-11-21
US20210128721A1 (en) 2021-05-06
MX2022011934A (en) 2022-10-20
BR112019015797A2 (en) 2020-03-17
EP3576780A1 (en) 2019-12-11
CN110430894A (en) 2019-11-08
CL2019002134A1 (en) 2019-11-22
CA3051252A1 (en) 2018-08-09
CO2019009234A2 (en) 2019-08-30
WO2018144775A1 (en) 2018-08-09
CN117224710A (en) 2023-12-15
AU2018214556A1 (en) 2019-08-15

Similar Documents

Publication Publication Date Title
SG11201906969PA (en) Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
SG11201903674YA (en) Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
SG11201901126UA (en) Combination therapy for cancer
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201907023UA (en) Method of reducing neutropenia
SG11201909572QA (en) Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
SG11201808990QA (en) Compositions for topical application of compounds
SG11201909949XA (en) Targeted immunotolerance
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201807421TA (en) The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201811432WA (en) Rna for cancer therapy
SG11201906947SA (en) Antibodies to alpha-synuclein and uses thereof
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201807597UA (en) Methods of treating depression using orexin-2 receptor antagonists
SG11201909825VA (en) Hsp90 inhibitor oral formulations and related methods